Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7523809 | 0.98 | PRMT5 (0.45) | PRMT5WDR77P2RY12ADORA2AADORA2B | |
| SCHEMBL2115365 | 0.93 | PRMT5 (0.46) | PRMT5WDR77ADORA2AADORA2BADORA3 | |
| SCHEMBL30901148 | 0.91 | ADORA2A (0.54) | PRMT5WDR77P2RY12ADORA2AADORA2B | |
| SCHEMBL439196 | 0.91 | ADORA2A (0.54) | PRMT5WDR77P2RY12ADORA2AADORA2B | |
| SCHEMBL9024698 | 0.91 | P2RY12 (0.49) | PRMT5WDR77P2RY12ADORA2AADORA2B | |
| SCHEMBL888000 | 0.87 | ADORA3 (0.43) | P2RY12ADORA2AADORA3 | |
| SCHEMBL2112012 | 0.87 | ADORA3 (0.43) | P2RY12ADORA3 | |
| SCHEMBL9294052 | 0.85 | ADORA2A (0.49) | P2RY12ADORA2AADORA2BADORA3 | |
| SCHEMBL2111737 | 0.85 | PRMT5 (0.45) | PRMT5WDR77 | |
| SCHEMBL9155236 | 0.85 | TAS1R3 (0.36) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230193258-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE | 2023-06-22 | — | — | US | disclosed |
| US-11208654-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200032255-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE | 2020-01-30 | — | — | US | disclosed |
| US-10253318-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180142239-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE | 2018-05-24 | — | — | US | disclosed |
| US-9688982-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2017-06-27 | — | — | US | disclosed |
| US-9200280-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2015-12-01 | — | — | US | disclosed |
| US-9200279-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2015-12-01 | — | — | US | disclosed |
| US-20140287987-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2014-09-25 | — | — | US | disclosed |
| US-8748405-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2014-06-10 | — | — | US | disclosed |
| US-20140066592-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2014-03-06 | — | — | US | disclosed |
| US-8158770-B2 | Content dependent inhibitors of cytidine deaminases and uses thereof | UNIVERSITY OF ROCHESTER (US) | 2012-04-17 | — | — | US | disclosed |
| US-20120065125-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110071210-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2011-03-24 | — | — | US | disclosed |
| EP-2125855-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-16 | — | — | US | disclosed |
| US-20080214436-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2008-09-04 | — | — | US | disclosed |
| WO-2008094254-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2008-08-07 | — | — | WO | disclosed |
| US-6379931-B1 | Chimeric DNA/RNA ribozymes containing propanediol | CITY OF HOPE | 2002-04-30 | — | — | US | disclosed |
| EP-0633890-B1 | SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS | ZENECA LTD (GB) | 1998-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214436-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | PRMT5 1550/4885WDR77 1773/4885P2RY12 2949/4885 |
| US-20120065125-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | PRMT5 1550/4885WDR77 1773/4885P2RY12 2949/4885 |
| US-20140066592-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | PRMT5 1550/4885WDR77 1773/4885P2RY12 2949/4885 |
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | DCTD, CDA, ADA | PRMT5 211/4885WDR77 504/4885P2RY12 3930/4885 |
| US-20180142239-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | PRMT5 1550/4885WDR77 1773/4885P2RY12 2949/4885 |
| US-11208654-B2 | Methods and compositions for the treatment of cancer or other diseases | HLA-DRB1, CD47, IL2 | PRMT5 1550/4885WDR77 1773/4885P2RY12 2949/4885 |
| US-20140287987-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | PRMT5 1550/4885WDR77 1773/4885P2RY12 2949/4885 |
| US-20200032255-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | PRMT5 1550/4885WDR77 1773/4885P2RY12 2949/4885 |
| US-20110071210-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | PRMT5 1550/4885WDR77 1773/4885P2RY12 2949/4885 |
| US-20230193258-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | PRMT5 1550/4885WDR77 1773/4885P2RY12 2949/4885 |
| US-10253318-B2 | Methods and compositions for the treatment of cancer or other diseases | HLA-DRB1, CD47, IL2 | PRMT5 1550/4885WDR77 1773/4885P2RY12 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.